VIRAL AND CELLULAR SURFACE ANTIGENS OF MURINE LEUKEMIAS AND MYELOMAS

SEROLOGICAL ANALYSIS BY IMMUNOELECTRON MICROSCOPY*

BY TADAO AOKI‡ AND TOSHITADA TAKAHASHI§

(From the Division of Immunology, Sloan-Kettering Institute for Cancer Research, New York 10021)

(Received for publication 12 October 1971)

In studying the relation of the envelope antigens of oncorna viruses (1) to the antigens of cells they infect, it is necessary to consider: (a) infection, the penetration of virus into the cell, which may possibly leave residual antigens at the cell surface (2); (b) virus-directed synthesis of cell-surface components unrelated to the construction of virions (3, 4); and (c) virus assembly at the cell surface, during which the nucleocapsid becomes progressively enveloped by an outer membrane which is continuous with the plasma membrane of the cell (until maturation is complete) and which may or may not differ from it morphologically, according to the type of virus concerned (5–7).

In addition to problems relating to the constitution of the viral envelope, and to modifications of cell-surface composition resulting from infection, there arises the important question of whether the maturation of virus can take place at any region of the cell surface, or whether this is in any way governed by the remarkable regional differentiation which has recently been recognized as characteristic of cell surfaces.

We have already reported that H-2 alloantigen and GCSA1 (a cell-surface murine leukemia virus (MuLV)-associated antigen) were not present on the envelope of MuLV from leukemia cells (Ec2G2) induced by passage A Gross virus, and that budding appeared to take place preferentially at H-2–GCSA– regions of the cell surface (4). In this communication we report an extension of these findings to other known antigens, cell-specified which contribute to the composition of the cell surface.

* The authors' work is supported in part by National Cancer Institute Grant CA 08748 and a grant from the John A. Hartford Foundation, Inc.
‡ Present address: Viral Leukemia and Lymphoma Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20014.
§ Present address: Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.

1 Abbreviations used in this paper: B6, C57BL/6; BALB, BALB/c; GCSA, Gross cell-surface antigen; GMuLV, Gross (wild-type) murine leukemia virus; GVEA, Gross viral envelope antigen; IEM, immunoelectron microscopy; MuLV, murine leukemia virus; SBMV, southern bean mosaic virus, xVEA, new myeloma virion antigen.
ANTIGENS OF MURINE LEUKEMIAS AND MYELOMAS

Materials and Methods

Serological Test Systems.—See Tables I and II. Medium 199 was used as the diluent and suspending medium.

Absorption of Antisera.—

In vitro: The test serum was diluted to two doubling dilutions below the end point of the cytotoxic test, mixed with an equal volume of packed washed cells, incubated for 30 min at 4°C, and recovered by centrifugation in the cold.

In vivo: To remove anti-mouse heteroantibody, the rat MuLV typing serum (W/Fu × BN)F1 anti-W/Fu(C57NT)D (10) was absorbed in vivo in 2-month-old C57BL/6 (B6) mice; 1 ml of undiluted antiserum was injected intraperitoneally and recovered 2½ hr later by cardiac puncture. The absorbed antiserum did not react with EL4 cells (GCSCA+) in immunoelectron microscopy (IEM) tests, confirming that absorption of heteroantibody was complete.

TABLE I

| Leukemia (test cell)                                                                 | Antisera                       | Specificity                          |
|------------------------------------------------------------------------------------|--------------------------------|--------------------------------------|
| B6 transplanted leukemia E2aG2, induced by passage A Gross virus; (genotype of B6 mice is H-2^b:θ-C3H:Ly-A.2:Ly-B.2) | B6/ H-2^b* anti-B6 leukemia EL4 | H-2^b(2, 6, 14, 22, 27, 28, 29, 33)  |
|                                                                                     | A/θ-AKR* anti-A strain spontaneous leukemia ASL1 | θ-C3H                               |
|                                                                                     | C3H/An anti-CE thymocytes       | Ly-A.2                               |
|                                                                                     | (C3H/An × B6/Ly-B.1*)F1         | Ly-B.2                               |
|                                                                                     | anti-B6 radiation leukemia      |                                      |
|                                                                                     | ERLD                            |                                      |
| Transplanted AKR spontaneous leukemia K36 ascites cells; (genotype of AKR mice is H-2^b:θ-AKR:1:Ly-A.2:Ly-B.1) | AKR/ H-2^b* anti-AKR leukemia K36 | H-2^b(1, 3, 8, 11, 25, 32)            |
|                                                                                     | C3H/An anti-AKR thymocytes      | θ-AKR                                |
|                                                                                     | C3H/An anti-CE thymocytes       | Ly-A.2                               |
|                                                                                     | B6/ H-2^b anti-CE thymocytes     | Ly-B.1                               |

* Congenic strains.

Antigen Labeling.—5–10 × 10^6 washed viable test cells were incubated in the relevant antiserum (considerable excess antibody was always used). After two washings, the cells were incubated with anti-mouse-γG/anti-southern bean mosaic virus (SBMV) F(ab')_2 or anti-rat-γG/anti-ferritin F(ab')_2 hybrid antibody. The concentration of hybrid antibody was approximately 0.05 mg/ml with respect to anti-γG. (For detailed information on the hybrid antibody preparation see references 11, 12.) After two more washings, the cells were incubated with SBMV (0.05 ml of 10 mg/ml) or ferritin (0.05 ml of 0.05 mg/ml, six times crystallized) and then were finally washed twice. The incubations were carried out for 30 min at 0°C with occasional shaking, and washings were done in the cold.

Electron Microscopy.—The final pellets of viable cells were covered with 2 ml of buffered 2% glutaraldehyde for 20 min at 0°C. After fixation for 60–90 min in cold buffered 1% osmium tetroxide, they were kept overnight in cold 0.5% uranyl acetate, then dehydrated with ethanol and embedded in Epon. Thin sections were cut on a Sorvall MT-2 ultramicrotome (Ivan Sorvall Inc., Norwalk, Conn.) with a diamond knife, stained with 5% uranyl acetate in alcoholic solution and lead citrate, and examined with a Siemens Elmoskop IA electron microscope (Siemens Corp., Electromedical Div., Iselin, N.J.).
More than 100 virions and 100 cells of each sample were observed to determine whether antigens are present on or absent from the viral envelopes and cell surfaces. In order to avoid observing the same cells in different sections of one embedded sample, thin sections were obtained from eight blocks of each specimen.

### TABLE II

| Antiserum                                | Absorbed with | Tested on |
|------------------------------------------|---------------|-----------|
| (B6 × DBA/2)F₁ anti-MOPC-70A (standard anti-PC.1 typing serum) (15) | —             | MOPC-70A BALB myeloma cells | Ec⁺G2 B6 leukemia cells | BALB spleen cells |
|                                        |               | Known antigens identified | GCSA (23),* | GCSA (23) | PC (15) |
| (B6 × DBA/2)F₁ anti-MOPC-70A (standard anti-PC.1 typing serum) (15) | BALB spleen | GCSA      | GCSA      | —      | —      |
|                                        | Ec⁺G2        | PC         | —         | —      | —      |
|                                        | BALB spleen  | —          | —         | —      | —      |
|                                        | + Ec⁺G2      | —          | —         | —      | —      |
|                                        | MOPC-70A     | —          | —         | —      | —      |
| Serum from untreated, aged autoimmune NZB mice | —             | See Results | GVEA† (4) | NT§      |
| (W/Fu × Bn)F₁ anti-W/Fu (C58NT) D (standard MuLV [Gross] typing serum prepared in rats) (10) | In vivo in young B6 mice | See Results | GCSA (23),§ | —      |
|                                        |              |            | GVEA (4)  | —      |

* GCSA, G (Gross) cell-surface antigen, previously designated G antigen (17).  
† GVEA, G (Gross) viral envelope antigen (4).  
§ NT, not tested.

### RESULTS

**H-2, θ, Ly-A, and Ly-B Antigens on the Two GCSA⁺ Leukemias, Ec⁺G2 (B6) and K36 (AKR).**—These observations are summarized in Fig. 1.

Ec⁺G2 (strain of origin: B6-genotype H-2b, θ-C3H, Ly-A.2, Ly-B.2): H-2b, θ-C3H, and Ly-A.2 antigens were detected on small discrete areas of the cell surface in some but not all sections (Figs. 2 and 3). Ly-B.2 was not demonstrable. A small proportion (approximately 1/5) of both budding and extracellular MuLV produced by Ec⁺G2 cells were labeled by anti-θ-C3H antiserum. The label invariably appeared on only a small sector of the envelope; in no case was the entire circumference labeled. H-2b, Ly-A.2, and Ly-B.2 antigens were not detected on virions at any stage of maturation (Fig. 1).
K36 (strain of origin: AKR-genotype H-2\textsuperscript{k}, θ-AKR, Ly-A.2, Ly-B.1): H-2\textsuperscript{k} and Ly-B.1 antigens were detected on small discrete areas of the cell surface in some but not all sections. θ-AKR and Ly-A.2 were not detectable. About one-fourth of the virions associated with K36, both incomplete (budding) as well as complete (extracellular), showed a restricted H-2\textsuperscript{k} sector on the viral envelope (Figs. 4 and 5). As the serum giving this reaction, H-2\textsuperscript{b} vs. H-2\textsuperscript{k} prepared in H-2 congenic mice, gave no reaction with Ec\textsuperscript{c}G2 cells (H-2\textsuperscript{c}) or its associated virions, this labeling of a sector on viral envelopes from K36 can confidently be ascribed to H-2\textsuperscript{k}, θ-AKR, Ly-A.2, and Ly-B.1 antigens were not detected on the viral envelope.

Once again, as in the case of θ-labeling of Ec\textsuperscript{c}G2 (above), the labeling produced by H-2 antiserum on K36 virions was restricted to small sectors of the viral envelope, and in no case was the entire circumference labeled (Figs. 4 and 5).

**Fig. 1.** Summary analysis of H-2, θ, Ly-A, and Ly-B antigens on the cell surface and the viral envelope of two Gross leukemias, Ec\textsuperscript{c}G2 and K36.

We shall be concerned here with known antigens of three classes: (a) the differentiation alloantigen (13, 14), PC (15), which is found on myeloma cells but not on leukemia cells, (b) the nonvirion MuLV-associated, cell-surface antigen, GCSA, and (c) the Gross viral envelope antigen, GVEA, which is found on Gross (wild-type) murine leukemia virus (GMuLV).

In order to study the possible representation of PC cell-surface antigen on virions produced by PC\textsuperscript{+} cells (myeloma cells and their nonmalignant counterparts), we employed the standard PC.1 typing serum \((B6 \times DBA/2)F_1\), ant
Fig. 2. EδG2 cells were reacted with the serum θ-ARK anti-θ-C3H and labeled with SBMV. Small areas on the cell surface are labeled with SBMV but the viral envelope is not labeled at all. X 144,000.

Fig. 3. EδG2 cells were reacted with the serum C3H/An anti-EC thymocytes (anti-Ly-A.2) and labeled with SMBV but the viral envelope is not labeled at all. X 72,000.

BALB myeloma MOPC-70A (15). According to the cytotoxic test, the method by which the PC antigenic system was described, this antiserum detects only PC antigen, but IEM reveals the presence of additional, MuLV-associated antibodies that are not apparent by cytotoxicity. A summary analysis of the data is given in Fig. 6, which is largely self-explanatory.

PC antigen was seen to be represented on discrete areas of the surface of PC+
spleen cells (Figs. 7 and 8), like all other cell-surface alloantigens so far studied (see above and reference 16). The reaction with EαG2 leukemia cell surfaces shows that anti-GCSA is present in the PC typing serum (although not demon-

Figs. 4 and 5. K36 cells were reacted with the serum H-2b anti-H-2k and labeled with SBMV. Small areas on both the cell surface and the envelope of budding viruses are labeled with SBMV. Fig. 4, × 72,000; Fig. 5, × 144,000.

strable by cytotoxicity) (Fig. 9). Furthermore, the antiserum contains antibody to a third antigen, tentatively named χVEA, which identifies a new virion antigen present on the myeloma virions but lacking from the leukemia cell virions both originally derived from passage A Gross virus (Figs. 9 and 10) and
| SERUM | ABSORBED | REACTED WITH | INTERPRETATION |
|-------|----------|--------------|----------------|
|       | MOPC-70A BALB myeloma cells (PC⁺) (GCSA⁺) | EμG2 Gross leukemia cells (PC⁺) (GCSA⁺) | Cells from immunized BALB spleen (PC⁺) (GCSA⁺) | |
| (B6 x DBA/2)F₁ anti-MOPC-70A myeloma cells | GCSA x VEA | GCSA | PC | Viornos from MOPC-70A myeloma cells have an envelope antigen (xVEA) that is absent from passage A Gross MuLV. |
| with normal BALB spleen cells | | | | xVEA is not PC. |
| with EμG2 Gross leukemia cells | | | | Confirm that xVEA is absent from passage A Gross MuLV. |
| with both of the above | xVEA | | | xVEA occurs only on virions, not on the cell surface. |
| with MOPC-70A myeloma cells | | | | Control; all activities removed by absorption with MOPC-70A |
| from untreated aged NZB mice | | | | Aged NZB mice form anti-GVEA. |
| (W/Fu x BN) anti-W/Fu C3HNTD (Standard rat MuLV Gross typing serum) in vivo in B6 mice to remove natural heteroantibody | GCSA x GVEA | GCSA (GVEA) | (all negative) | GVEA (as well as xVEA) is present on virions from MOPC-70A cells |

Fig. 6. Summary analysis of GMuLV antigens and PC alloantigen on myeloma cells, leukemia cells, and spleen cells.
Fig. 7. BALB spleen cells (middle-size lymphocytes) were reacted with the standard PC.1 typing serum (B6 × DBA/2) F1 anti-BALB myeloma MOPC-70A and labeled with SBMV. Small sectors on the cell surface are labeled with SBMV. × 18,000.

Fig. 8. Higher magnification of one area in Fig. 7, showing several of the discrete SBMV-marked PC.1 sectors. × 30,000.
The presence of \( \chi \text{VEA} \) on the myeloma virions precludes an absolute answer as to whether PC may be represented on the myeloma virions; this would require a demonstration that absorption with \( \chi \text{VEA}^- \text{PC}^- \) cells (of which no examples are known so far) would remove all reaction with myeloma virions while leaving PC cell-surface reactivity intact.

The two other entries in Fig. 6 are included as controls. The serum of aged (autoimmune) mice of the NZB strain contains anti-GVEA antibody reactive with both the myeloma (Figs. 12 and 13) and the leukemia virions (Fig. 14), and so does the standard GMuLV typing serum produced by rats (Figs. 15 and 16). The latter, as expected, also gave cell-surface reactions referable to GCSA (and perhaps also to \( \text{GxF} \) antigen, see reference 17). The reaction of autoimmune NZB mouse serum with the myeloma cell surface has not been identified.

**DISCUSSION**

**Alloantigens.**—In a previous study, neither \( H-2^b \) alloantigen nor the MuLV-associated cell-surface antigen, GCSA, was present on the envelope of virions produced by cells bearing these antigens. This conclusion can now be extended to the differentiation alloantigens (13, 14), \( \theta \), Ly-A, and Ly-B. The occasional \( H-2^k \) labeling of a small sector of some virions coming from \( H-2^k \) leukemia cells is a fact to take note of, for it was not seen with \( H-2^b \), and these two \( H-2 \) alleles confer, respectively, sensitivity and resistance to leukemia induction by GMuLV (18-20). We noted earlier that the invariable absence of \( H-2^b \) from virions produced by \( E\sigma G2 \) leukemia cells suggests that they are made preferentially at \( H-2^- \) regions of the cell surface; evidently the same may not hold for \( H-2^b \) and this may have something to do with the mediation of susceptibility of \( H-2^b \) mice vs. \( H-2^k \) mice.

The occasional \( \theta^- \) labeling of some virions produced by \( E\sigma G2 \) leukemia cells may similarly indicate that MuLV does not preferentially select either \( \theta^- \) or \( \theta^+ \) regions of the cell surface for maturation sites; and in fact the fraction of virions showing a \( \theta^- \)-labeled sector is roughly equivalent to the fraction of the \( E\sigma G2 \) cell surface which bears \( \theta^- \)-antigen. In such circumstances it is not very surprising to find that such an alloantigen is occasionally and fortuitously associated with the surface of the virion. It seems highly unlikely that the respective alloantisera could neutralize any but an insignificant fraction of the infectivity of the virus population concerned.

Turning to the general topic of cell-surface constitution, it is interesting that according to IEM the phenotype of the two leukemias, with respect to their surface differentiation alloantigens (13, 14), was \( \theta^- \text{Ly-A}^+ \text{Ly-B}^- (E\sigma G2) \) and \( \theta^- \text{Ly-A}^- \text{Ly-B}^+ (K36) \) (Fig. 1). This accords with serological absorption tests (personal observations). Clearly the plasma membrane components recognized from wild-type Gross virus. The absorption tests illustrated in Figs. 6 and 11 confirm these conclusions.
FIG. 9. E2G2 cells were reacted with the standard PC.1 typing serum (B6 X DBA/2) F1 anti-BALB myeloma MOPC-70A and labeled with SBMV. One large sector on the cell surface is labeled with SBMV, showing GCSA+, but the envelope of budding virus in the middle of GCSA+ area is not labeled at all. X 144,000.

FIG. 10. BALB myeloma MOPC-70A cells were reacted with the standard PC.1 typing serum (B6 X DBA/2) F1 anti-MOPC-70A and labeled with SBMV. Both the discrete areas on the cell surface and the entire envelope of budding viruses are labeled with SBMV. X 144,000.
as θ-antigen or as antigens of the Ly series are not essential to cell viability; for in fact they are limited to certain cell types only. Their loss from malignant cells therefore may be consequential, which may not be the case with the H-2 locus, whose products are found on possibly all cells and may constitute essential elements of the plasma membrane. (Loss of the antigens of one H-2 haplotype from malignant cells occurs readily under circumstances of immunoselection, but losses of entire H-2 complements have not been found; one explanation of this is that the products of the H-2 locus itself are essential to cell viability [see references 13 and 21].) The fact that both leukemias retain at least one of the markers, θ, Ly-A, and Ly-B, identifies them as derivatives of the T lymphocyte (22). It seems highly likely therefore that the selective loss of these antigens from the two leukemias (assuming the losses to be absolute) has produced phenotypes that have no counterpart in the nonmalignant precursor population. Whether the loss is due to exclusion of the coding genes, as is probably the case with the H-2 haplotype losses mentioned above, or whether it is epigenetic, is unknown.

**MuLV-Related Antigens.**—The finding of a new VEA on virions produced by myeloma MOPC-70A was an unexpected outcome of testing for PC.1 antigen. The PC typing serum is monospecific for PC.1 antigen in cytotoxic tests, but IEM shows it contains anti-GCSA (cell-surface antigen specified by GMuLV) and also antibody to the new VEA antigen which denotes the virus produced by MOPC-70A as an MuLV subtype vis-à-vis passage A Gross MuLV.

The identification of the MOPC-70A-myeloma virus as a distinct subtype may help explain the usual phenotype of these cells, which is GCSA+Gxx⁻ (23). (In normal mice, Gxx is a thymocyte-differentiation alloantigen whose expression is dependent on two cellular genes, one of them at the Gxx locus in linkage group IX; if MuLV is productively expressed, however, the rule is that Gxx⁻ antigen will be expressed, regardless of the inherited cellular genotype. Thus MuLV⁻ to MuLV⁺ conversion of Gxx⁻ cells is generally accompanied by Gxx⁻ to Gxx⁺ conversion.) The MOPC-70A virus may now perhaps be classed with the Friend, Moloney, and Rauscher variants, all of which induce the GCSA⁺ but not the Gxx⁺ (23) phenotype. The Gxx⁻ to Gxx⁺ conversion may therefore be a particular function of wild-type GMuLV as represented in AKR and C58 mice and the derivative passage A Gross virus.

**SUMMARY**

Immunoelectron microscopy (IEM) of mouse cells which were productively infected with murine leukemia virus (MuLV) yielded the following conclusions:

![Fig. 11. BALB myeloma MOPC-70A cells were reacted with the standard PC.1 typing serum (B6 × DBA/2) F₁ anti-MOPC-70A previously absorbed with EcPG2 cells, and labeled with SBMV. The cell surface is nearly negative, but the entire envelope of budding virus remains labeled with SBMV, showing GVEA of MOPC-70A virions different from GVEA of EcG2 virions. X 144,000.](image-url)
Figs. 12 and 13. BALB myeloma MOPC-70A cells were reacted with the serum of aged (autoimmune) NZB mice and labeled with SBMV. The entire envelope of budding viruses at the initial stage (Fig. 12) and at the advanced stage (Fig. 13) and minute areas on the cell surface are labeled with SBMV. × 144,000.

Fig. 14. E2+G2 cells were reacted with the serum of aged (autoimmune) NZB mice and labeled with SBMV. The entire envelope of both complete and budding viruses is labeled with SBMV but the cell surface is not labeled at all. × 144,000.
With two exceptions, the alloantigens H-2, θ, Ly-A, and Ly-B were not present on complete or incomplete virions produced by cells bearing these antigens. The exceptions were H-2^k (but not H-2^p) and θ; both appeared on only a minority of virions and never on more than a small part of the circumference.
The incidental discovery of an additional envelope antigen on virions produced by a BALB/c mouse myeloma but lacking from passage A Gross virions distinguishes these two viruses as MuLV subtypes; it also illustrates that IEM can be applied as a primary tool for antigenic analysis, as well as for its usual purpose of finding out where antigens are situated.

We are indebted to Dr. H. A. Wood for supply of SBMV; Doctors L. J. Old, E. A. Boyse, and E. de Harven for valuable advice and discussion; and Mr. M. P. Lardis, Miss S. Ohno, and P. A. Johnson for excellent technical assistance.

**BIBLIOGRAPHY**

1. Nowinski, R. C., L. J. Old, N. H. Sarkar, and D. H. Moore. 1970. Common properties of oncogenic RNA viruses (oncornaviruses). *Virology*. 42:1152.

2. Miyamoto, K., and R. V. Gilden. 1971. Electron microscopic studies of tumor viruses. I. Entry of murine leukemia virus into mouse embryo fibroblasts. *J. Virol*. 7:395.

3. Old, L. J., and E. A. Boyse. 1965. Antigens of tumors and leukemias induced by viruses. *Fed. Proc.* 24:1009.

4. Aoki, T., E. A. Boyse, L. J. Old, E. de Harven, U. Hammerling, and H. A. Wood. 1970. G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. *Proc. Nat. Acad. Sci. U.S.A.* 65:569.

5. de Harven, E. 1968. Morphology of murine leukemia viruses. In *Experimental Leukemia*. M. Rich, editor. Appleton-Century-Crofts, New York. 97.

6. Kates, M., A. C. Allison, D. A. J. Tyrell, and A. T. James. 1962. Origin of lipids of influenza virus. *Cold Spring Harbor Symp. Quant. Biol.* 27:293.

7. Hoyle, L. 1962. The entry of myxoviruses into the cell. *Cold Spring Harbor Symp. Quant. Biol.* 27:113.

8. Reif, A. E., and J. M. V. Allen. 1964. The AKR thymic antigen and its distribution in leukemias and nervous tissues. *J. Exp. Med.* 120:413.

9. Boyse, E. A., M. Miyazawa, T. Aoki, and L. J. Old. 1968. Ly-A and Ly-B: two systems of lymphocyte iso-antigens in the mouse. *Proc. Roy. Soc. Ser. B Biol. Sci.* 170:175.

10. Geering, G., L. J. Old, and E. A. Boyse. 1966. Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of Gross virus and other murine leukemia viruses. *J. Exp. Med.* 124:753.

11. Hämmerling, U., T. Aoki, E. de Harven, E. A. Boyse, and L. J. Old. 1968. Use of hybrid antibody with anti-yG and anti-ferritin specificities in locating cell surface antigens by electron microscopy. *J. Exp. Med.* 128:1461.

12. Hämmerling, U., T. Aoki, H. A. Wood, L. J. Old, E. A. Boyse, and E. de Harven. 1969. New visual markers of antibody for electron microscopy. *Nature (London).* 223:1158.

13. Boyse, E. A., and L. J. Old. 1969. Some aspects of normal and abnormal cell surface genetics. *Annu. Rev. Genet.* 3:269.

14. Hämmerling, U. Changes of antigenic surface patterns in differentiating lymphocytes. In The 9th Canadian Research Conference, Montreal. In press.
15. Takahashi, T., L. J. Old, and E. A. Boyse. 1970. Surface alloantigens of plasma cells. 
J. Exp. Med. 131:1325.
16. Aoki, T., U. Hämmerling, E. de Harven, E. A. Boyse, and L. J. Old. 1969. Anti-
genic structure of cell surfaces. An immunoferritin study of the occurrence 
and topography of H-2, θ, and TL alloantigens on mouse cells. J. Exp. Med. 
130:979.
17. Old, L. J., E. A. Boyse, and E. Stockert. 1965. The G (Gross) leukemia antigen. 
Cancer Res. 25:813.
18. Lilly, F., E. A. Boyse, and L. J. Old. 1964. Genetic basis of susceptibility to viral 
leukemogenesis. Lancet. 2:1207.
19. Lilly, F. 1969. The role of genetics in Gross virus leukemogenesis. In Comparative 
Leukemia Research. R. M. Dutcher, editor. S. Karger, New York. 213.
20. Boyse, E. A., L. J. Old, and E. Stockert. 1971. The relation of linkage group IX 
to leukemogenesis in the mouse. In Proceedings of the Conference on RNA 
Viruses and Host Genome in Oncogenesis, Amsterdam. P. Emmelot and P. 
Bentvelzen, editors. North Holland Publishing Co., Amsterdam. In press.
21. Bjaring, B., and G. Klein. 1968. Antigenic characterization of heterozygous 
mouse lymphomas after immunoselection in vivo. J. Nat. Cancer Inst. 41:1411.
22. Roitt, E. M., M. F. Greaves, G. Torrigiani, J. Brostoff, and J. H. L. Playfair. 
1969. The cellular basis of immunological responses. Lancet. 2:367.
23. Stockert, E., L. J. Old, and E. A. Boyse. 1971. The GIX System. A cell surface 
alloantigen associated with murine leukemia virus; implications regarding 
chromosomal integration of the viral genome. J. Exp. Med. 133:1334.